New obesity guideline reframes diagnosis beyond BMI to catch disease earlier

Clinical Takeaway: Screen adults annually using BMI and weight trends—but diagnose and stage obesity using both BMI and central adiposity measures, then tailor care with a chronic disease model and risk staging.

The ADA/Obesity Association’s 2026 Standards of Care section on screening, diagnosis, evaluation, and staging of obesity introduces a major shift from weight-centric definitions toward a multidimensional, risk-based framework designed to detect obesity earlier and guide individualized treatment.

“Obesity is not simply a matter of weight—it is a multifactorial, chronic disease requiring systematic, person-centered care,” said guideline author Victoria Bouhairie, MD, emphasizing the move toward actionable clinical pathways.

A key update is earlier identification. Clinicians are advised to track longitudinal weight gain—not just absolute BMI—with sustained increases of ~1–1.5 kg/year over ≥3 years signaling elevated risk even before obesity thresholds are reached. Annual BMI screening remains the standard, but the guideline stresses that BMI alone is insufficient and may miss up to half of individuals with excess adiposity.

Diagnosis now explicitly integrates central adiposity. Adults with BMI in the overweight range (25–29.9 kg/m²; lower for Asian populations) should be diagnosed with obesity if waist circumference or waist-to-height ratio indicates excess visceral fat. This change addresses long-standing underdiagnosis and reflects evidence that central adiposity better predicts cardiometabolic risk than BMI alone.

The guideline also formalizes race- and ethnicity-specific thresholds, particularly lower BMI cutoffs for individuals of Asian background, and highlights the role of alternative measures (eg, waist circumference, body composition) when BMI may misclassify risk, such as in older adults or those with high muscle mass.

Following diagnosis, clinicians should perform a comprehensive, biopsychosocial evaluation encompassing medical, behavioral, and social determinants of health, along with screening for weight-promoting medications, mental health conditions, and obesity-related comorbidities. Risk stratification using tools such as the Edmonton Obesity Staging System is recommended to guide treatment intensity and prognosis.

Importantly, obesity care is framed explicitly as chronic disease management. Shared decision-making, goal setting, and longitudinal follow-up—often monthly early in pharmacotherapy—are emphasized, with ongoing assessment of efficacy, safety, and barriers. Although this section does not include specific pharmacologic recommendations, it underscores identifying weight-promoting medications and aligning future treatment choices with staging and risk.

The guideline also prioritizes reducing weight stigma, encouraging clinicians to ask permission before discussing weight, use nonstigmatizing language, and assess prior experiences of bias. System-level changes—such as embedding obesity workflows, EHR tools, and dedicated “weight-focused visits”—are recommended to improve care delivery.

What’s changed

• Obesity diagnosis expanded beyond BMI to include central adiposity (waist circumference or waist-to-height ratio)
• Overweight + central adiposity now qualifies as obesity diagnosis
• Greater emphasis on longitudinal weight gain trends as an early risk signal
• Standardized use of race/ethnicity-specific BMI thresholds
• Integration of structured risk staging (eg, Edmonton Obesity Staging System) into routine care
• Stronger focus on chronic disease management, follow-up cadence, and care pathways
• New emphasis on identifying weight-promoting medications and addressing weight stigma in clinical workflows

Overall, the guideline reframes obesity as a heterogeneous, chronic disease requiring earlier detection, more precise diagnosis, and individualized, staged care—aimed at improving outcomes while addressing persistent gaps in recognition and treatment.

Source: American Diabetes Association Professional Practice Committee for Obesity. 2026 June 29. Diabetes, Obesity, and CardioMetabolic CARE. Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity—2026